Marc P. Bonaca

29.5k total citations · 9 hit papers
279 papers, 15.3k citations indexed

About

Marc P. Bonaca is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marc P. Bonaca has authored 279 papers receiving a total of 15.3k indexed citations (citations by other indexed papers that have themselves been cited), including 184 papers in Cardiology and Cardiovascular Medicine, 151 papers in Surgery and 50 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marc P. Bonaca's work include Antiplatelet Therapy and Cardiovascular Diseases (115 papers), Peripheral Artery Disease Management (95 papers) and Acute Myocardial Infarction Research (60 papers). Marc P. Bonaca is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (115 papers), Peripheral Artery Disease Management (95 papers) and Acute Myocardial Infarction Research (60 papers). Marc P. Bonaca collaborates with scholars based in United States, United Kingdom and Canada. Marc P. Bonaca's co-authors include Marc S. Sabatine, Sabina A. Murphy, Deepak L. Bhatt, Stephen D. Wiviott, Lawrence A. Leiter, Ofri Mosenzon, Darren K. McGuire, John Wilding, Thomas A. Zelniker and Avivit Cahn and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Marc P. Bonaca

252 papers receiving 15.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

2018 4.3k citations Stephen D. Wiviott, Marc P. Bonaca et al. New England Journal of Medicine profile →
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

2018 1.9k citations Thomas A. Zelniker, Stephen D. Wiviott et al. profile →
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

2018 836 citations Marc P. Bonaca et al. profile →
Vorapaxar in the Secondary Prevention of Atherothrombotic Events

2012 656 citations David A. Morrow, Eugene Braunwald et al. New England Journal of Medicine profile →
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus

2019 534 citations Thomas A. Zelniker, Stephen D. Wiviott et al. Circulation profile →
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

2017 491 citations Marc P. Bonaca, Patrice Nault et al. Circulation profile →
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus

2020 313 citations Thomas A. Zelniker, Marc P. Bonaca et al. Circulation profile →
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease

2016 249 citations Marc P. Bonaca, Deepak L. Bhatt et al. Journal of the American College of Cardiology profile →
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial

2025 25 citations Marc P. Bonaca, Andrei‐Mircea Catarig et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marc P. Bonaca United States	46	7.1k	6.7k	5.9k	3.2k	2.2k	279	15.3k
Benjamin M. Scirica United States	56	5.8k 0.8×	12.6k 1.9×	6.6k 1.1×	2.5k 0.8×	1.2k 0.6×	274	19.2k
Stefan Hantel Germany	27	9.4k 1.3×	4.9k 0.7×	4.7k 0.8×	4.0k 1.3×	1.2k 0.6×	63	13.8k
Kathy Wolski United States	47	6.1k 0.9×	3.5k 0.5×	8.7k 1.5×	3.5k 1.1×	1.4k 0.6×	111	16.5k
David Fitchett Canada	47	12.8k 1.8×	5.9k 0.9×	6.8k 1.2×	5.3k 1.7×	1.9k 0.9×	200	18.7k
Mark C. Petrie United Kingdom	60	3.3k 0.5×	12.7k 1.9×	4.5k 0.8×	1.5k 0.5×	1.6k 0.7×	317	16.9k
Jean MacFadyen United States	42	3.3k 0.5×	4.1k 0.6×	8.1k 1.4×	1.9k 0.6×	998 0.5×	56	15.3k
Thomas Moritz United States	40	3.9k 0.5×	4.1k 0.6×	3.5k 0.6×	1.2k 0.4×	1.3k 0.6×	107	10.3k
Christian T. Ruff United States	44	4.3k 0.6×	9.3k 1.4×	2.6k 0.4×	1.9k 0.6×	866 0.4×	175	14.5k
Felicita Andreotti Italy	45	1.9k 0.3×	10.1k 1.5×	5.8k 1.0×	1.1k 0.4×	935 0.4×	179	15.2k
Terje R. Pedersen Norway	68	7.9k 1.1×	8.2k 1.2×	16.7k 2.8×	1.6k 0.5×	1.8k 0.8×	171	25.2k

Countries citing papers authored by Marc P. Bonaca

Since Specialization

Citations

This map shows the geographic impact of Marc P. Bonaca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc P. Bonaca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc P. Bonaca more than expected).

Fields of papers citing papers by Marc P. Bonaca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc P. Bonaca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc P. Bonaca. The network helps show where Marc P. Bonaca may publish in the future.

Co-authorship network of co-authors of Marc P. Bonaca

This figure shows the co-authorship network connecting the top 25 collaborators of Marc P. Bonaca. A scholar is included among the top collaborators of Marc P. Bonaca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc P. Bonaca. Marc P. Bonaca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harrington, Josephine, Patrícia O. Guimarães, Andrew P. Ambrosy, et al.. (2025). Heart failure with preserved ejection fraction therapeutics: in search of the pillars. Heart Failure Reviews. 30(5). 1005–1014. 2 indexed citations

Zimerman, André, Frederick Kamanu, Giorgio Melloni, et al.. (2025). Polygenic risk score for coronary artery disease across the spectrum of atherosclerotic disease. European Journal of Preventive Cardiology.

Eikelboom, John W., Hardi Mundl, John H. Alexander, et al.. (2024). Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials. Journal of the American College of Cardiology. 83(6). 669–678. 4 indexed citations

Bonaca, Marc P., Geoffrey D. Barnes, Rupert Bauersachs, et al.. (2024). Antithrombotic Strategies for Patients With Peripheral Artery Disease. Journal of the American College of Cardiology. 84(10). 936–952. 3 indexed citations

Bonaca, Marc P., Andrei‐Mircea Catarig, Kim Christian Houlind, et al.. (2024). Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes. European Heart Journal - Cardiovascular Pharmacotherapy. 10(8). 728–737. 12 indexed citations

Goldenberg, Neil A., Sam Schulman, John M. Kittelson, et al.. (2024). Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years. Journal of Thrombosis and Haemostasis. 23(2). 651–656.

Yuan, Žhong, Bennett Levitan, Hsiaowei Deng, et al.. (2024). Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association. 13(8). e032782–e032782. 3 indexed citations

Mcdermott, Mary, Karen J. Ho, Olamide Alabi, et al.. (2023). Disparities in Diagnosis, Treatment, and Outcomes of Peripheral Artery Disease. Journal of the American College of Cardiology. 82(24). 2312–2328. 20 indexed citations

Eid, Mark A., Jonathan Barnes, Andrea M. Austin, et al.. (2023). Trends of Concomitant Diabetes and Peripheral Artery Disease and Lower Extremity Amputation in US Medicare Patients, 2007 to 2019. Circulation Cardiovascular Quality and Outcomes. 16(6). e009531–e009531. 11 indexed citations

10.

Lau, Emily S., Eugene Braunwald, David A. Morrow, et al.. (2021). Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. Circulation. 143(7). 685–695. 20 indexed citations

11.

Marston, Nicholas, Yared Gurmu, Giorgio Melloni, et al.. (2020). The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation. 141(20). 1600–1607. 65 indexed citations

12.

Zelniker, Thomas A., Marc P. Bonaca, Remo H.M. Furtado, et al.. (2020). Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation. 141(15). 1227–1234. 313 indexed citations breakdown →

13.

Furtado, Remo H.M., Marc P. Bonaca, Itamar Raz, et al.. (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 139(22). 2516–2527. 235 indexed citations

14.

Beckman, Joshua A., Meredith S. Duncan, Scott M. Damrauer, et al.. (2019). Microvascular Disease, Peripheral Artery Disease, and Amputation. Circulation. 140(6). 449–458. 116 indexed citations

15.

Zelniker, Thomas A., Stephen D. Wiviott, Itamar Raz, et al.. (2019). Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 139(17). 2022–2031. 534 indexed citations breakdown →

16.

Bonaca, Marc P., Patrice Nault, Robert P. Giugliano, et al.. (2017). Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. Circulation. 137(4). 338–350. 491 indexed citations breakdown →

17.

Bonaca, Marc P., Mark A. Creager, Jeffrey W. Olin, et al.. (2016). Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar. JACC: Cardiovascular Interventions. 9(20). 2157–2164. 29 indexed citations

18.

Magnani, Giulia, Marc P. Bonaca, Eugene Braunwald, et al.. (2015). Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. Journal of the American Heart Association. 4(3). e001505–e001505. 56 indexed citations

19.

Bonaca, Marc P., Benjamin M. Scirica, Mark A. Creager, et al.. (2013). Vorapaxar in Patients With Peripheral Artery Disease. Circulation. 127(14). 1522–1529. 210 indexed citations

20.

Morrow, David A., Eugene Braunwald, Marc P. Bonaca, et al.. (2012). Vorapaxar in the Secondary Prevention of Atherothrombotic Events. New England Journal of Medicine. 366(15). 1404–1413. 656 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact